Lupin Ltd — Capital/Financing Update 2018

Nov 12, 2018

==> picture [169 x 32] intentionally omitted <==

----- Start of picture text ----- Press Release----- End of picture text -----

==> picture [45 x 53] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin launches generic Atovaquone Oral Suspension USP in the US

Mumbai, Baltimore, November 12, 2018 : Pharma major Lupin announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron® oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMPSMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately USD 119 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13[th] largest generics pharmaceutical company in terms of market capitalization (30[th] September 2018, Bloomberg) and the 8[th] largest generics pharmaceutical company in terms of revenues (30[th] June 2018, Bloomberg LTM) globally. The Company is the 3[rd] largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3[rd] largest Indian pharmaceutical company by global revenues (30[th] June 2018, Bloomberg LTM); 6[th] largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31[st] March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66402137

*Safe Harbor Statement Mepron® is a registered trademark of Glaxosmithkline LLC.